Clinical trials: Adolescent Bipolar Disorder
Bipolar Disorder
Lamictal as Add-on Treatment for Bipolar I Disorder in Pediatric Patients
The study will be a multi-center, parallel, group, placebo control, double-blind, randomized controlled trial of lamictal as add-on maintenance treatment in pediatric outpatients (aged 10 to 17 years) diagnosed with Bipolar I…
- Trial name
- NCT00723450
- Testing
- lamictal
- Where
- 46 sites in United States
- Volunteers
- 301 people
- Sponsor
- GlaxoSmithKline
Bipolar Disorder
Metformin for Overweight & OBese ChILdren and Adolescents With BDS Treated With SGAs
A prospective, large, pragmatic, randomized trial to study the impact of METFORMIN and healthy lifestyle intervention (LIFE) vs.
- Trial name
- MOBILITY (NCT02515773)
- Testing
- Metformin, healthy lifestyle intervention (LIFE)
- Where
- 29 sites in United States
- Volunteers
- 1,565 people
- Sponsor
- Melissa Delbello
Pediatric Bipolar Disorder
Omega-3 Fatty Acid Adjunctive to Open-Label Aripiprazole for the Treatment of Bipolar Disorder in Children and Adolescents
This will be a 12 week, double blind study of omega-3 fatty acids vs. placebo adjunctive to open-label aripiprazole treatment in children and adolescents (ages 6-17) who meet DSM-IV criteria for bipolar disorder (BPD) (currently…
- Trial name
- NCT00592683
- Testing
- Aripiprazole, fish oil
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Massachusetts General Hospital
Bipolar I Depression
Lurasidone Pediatric Bipolar Study
A study to evaluate efficacy and safety of flexibly dosed Lurasidone in children and adolescents with bipolar I depression
- Trial name
- Illuminate (NCT02046369)
- Testing
- Lurasidone
- Where
- 66 sites in United States, Bulgaria and 9 more
- Volunteers
- 350 people
- Sponsor
- Sumitomo Pharma America, Inc.
Bipolar Disorder, Weight Gain
Topiramate vs. Placebo in Preventing Weight Gain in Bipolar Disorder Treated With Olanzapine
The primary objective of this study is to examine the efficacy of topiramate in combination with olanzapine for the prevention of weight gain in youth with bipolar disorder.
- Trial name
- NCT00394095
- Testing
- Topiramate
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- University of Cincinnati
Bipolar Disorder
Improving Adherence in Adolescents and Young Adults With Bipolar Disorder
Although poor medication adherence occurs in more than 65% of adolescent and young adults (AYA) with bipolar disorder (BD) and is associated with poor recovery, high rates of relapse, and a 5.2 fold increased suicide risk, there…
- Trial name
- IGNITE (NCT04348604)
- Testing
- Customized Adherence Enhancement for Adolescents and Young Adults (CAE-AYA), Enhanced Treatment as Usual (ETAU)
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Case Western Reserve University
Bipolar Disorder, Bipolar Depression
Uridine Adolescent Bipolar Depression Randomized Controlled Trial
This is a randomized, double-blind, placebo-controlled study of the investigational drug uridine as a treatment for depressed adolescents with bipolar disorder (i.e. "bipolar depression").
- Conditions
- Bipolar Disorder, Bipolar Depression, Manic Depression
- Trial name
- NCT01805440
- Testing
- Uridine
- Where
- United States
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- University of Utah
Bipolar Disorder
Extension Study Evaluating The Safety And Tolerability Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder
This 26-week open-label extension study is designed to provide information on the safety and tolerability of oral ziprasidone (20-80 mg BID (twice daily) with meals) during long-term administration in children and adolescents…
- Trial name
- NCT03768726
- Testing
- Ziprasidone
- Where
- 9 sites in United States
- Volunteers
- 23 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Substance Use Disorders, Bipolar Disorder
Treatment With Quetiapine for Youth With Substance Use Disorders and Severe Mood Dysregulation
This study proposes to use quetiapine as an adjunct treatment to treatment as usual to improve both substance use disorder (SUD) and mood symptoms in youth with SUD and severe mood dysregulation (SMD).
- Conditions
- Substance Use Disorders, Bipolar Disorder, Mood Disorders
- Trial name
- NCT02845453
- Testing
- Quetiapine
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Boston Medical Center
Bipolar Disorder
Aripiprazole in Children and Adolescents With Bipolar I Disorder
The purpose of this trial is to test the safety and efficacy of two doses of aripiprazole in child and adolescent patients with bipolar I disorder, manic or mixed episode with or without psychotic features.
- Trial name
- NCT00110461
- Testing
- Aripiprazole
- Where
- 53 sites in United States
- Volunteers
- 296 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Bipolar Disorder
Ziprasidone in Pediatric Bipolar Disorder
This is a 6 week, open-label, blinded-rater, randomized, controlled, pilot study designed to determine the dosing, safety and efficacy of ziprasidone in the treatment of pediatric bipolar disorder (PBD).
- Trial name
- NCT00622739
- Testing
- Ziprasidone
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Baylor College of Medicine
Bipolar Depression
Pediatric Bipolar Depression
The purpose of this study is to determine if quetiapine fumarate extended-release (quetiapine XR or SEROQUEL® XR) 150 to 300 mg/day taken by itself is effective and safe in treating children or adolescents aged 10 to 17 with…
- Trial name
- NCT00811473
- Testing
- Quetiapine XR
- Where
- 48 sites in United States, Colombia and 5 more
- Volunteers
- 193 people
- Sponsor
- AstraZeneca
Bipolar Disorder
Safety and Efficacy of Ziprasidone in Children and Adolescents With Bipolar I Disorder (Manic or Mixed)
The purpose of this study is to determine if flexibly-dosed ziprasidone is safe and effective for the treatment of children and adolescents (ages 10-17) with bipolar I disorder (manic or mixed).
- Trial name
- NCT00257166
- Testing
- Ziprasidone oral capsules
- Where
- 50 sites in United States
- Volunteers
- 238 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Schizophreniform Disorder, Schizoaffective Disorder
Open-label Ziprasidone Study for Psychosis Treatment in Adolescents
This open-label study will assess the medication Geodon® (Ziprasidone) in pediatric patients, aged 13-17, diagnosed with psychotic disorder.
- Conditions
- Schizophreniform Disorder, Schizoaffective Disorder, Psychosis, Depressive Disorder, Major
- Trial name
- NCT00421954
- Testing
- Ziprasidone
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- New York State Psychiatric Institute
Schizophrenia, Schizoaffective Disorder
Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth (Satiety) Study
The purpose of this study is to get a better understanding of the side effect burden and identify predictors of psychotic, mood and aggressive disorders in children and adolescents.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychotic Disorder, Not Otherwise Specified
- Trial name
- SATIETY (NCT01269710)
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of North Carolina, Chapel Hill
Pediatric Bipolar Disorder
Invega (Paliperidone) for the Treatment of Mania in Children and Adolescents Ages 6-17 With Bipolar Disorder
This will be an 8-week open-label trial, using daily doses of paliperidone (Invega) in the treatment of children and adolescents who meet DSM-IV criteria of Bipolar I, Bipolar II, or Bipolar Spectrum Disorder.
- Trial name
- NCT00592358
- Testing
- paliperidone
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Massachusetts General Hospital
Bipolar Youth Treated With Second-generation Antipsychotics
SGA-induced Metabolic Syndrome in Bipolar Youth
The investigators tested the hypothesis that long-chain omega-3 (LCn-3) fatty acid supplementation will attenuate the adverse cardiometabolic effects of second-generation antipsychotics exposure in first-episode adolescent manic…
- Trial name
- NCT01858948
- Testing
- Omega, Quetiapine fumarate
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Cincinnati